三阴性乳腺癌新辅助铂类应用专家共识(2023版)  

Experts consensus on platinum-based neoadjuvant therapy for triple negative breast cancer(2023 version)

作　　者：广东省医学会乳腺病学分会(广东省医学会乳腺病学分会青年委员会) 长江学术带乳腺联盟 重庆市医学会乳腺病分会 广东省预防医学会乳腺癌防治专业委员会 王坤[2] 张剑[3] 张毅 胡泓 李恒宇 齐晓伟 邱鹏飞[7] 谢菲[8] 张刘璐 Breast Disease Branch of Guangdong Medical Association(Youth Committee of Breast Disease Branch of Guangdong Medical Association);Breast Cancer Study Group Along the Yangtze River(YBCSG);Breast Disease Branch of Chongqing Medical Association;Breast Cancer Prevention and Treatment Committee of Guangdong Preventive Medicine Association;Wang Kun(不详;Department of Breast Cancer,Cancer Center,Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou 510080,China)

机构地区：[1]不详 [2]南方医科大学附属广东省人民医院(广东省医学科学院)乳腺肿瘤科,510080 [3]复旦大学附属肿瘤医院 [4]陆军军医大学西南医院 [5]深圳市人民医院 [6]海军军医大学附属上海长海医院 [7]山东省肿瘤医院 [8]北京大学人民医院 [9]广东省人民医院

出　　处：《中华乳腺病杂志（电子版）》2024年第1期1-10,共10页Chinese Journal of Breast Disease(Electronic Edition)

摘　　要：新辅助治疗是早期高危三阴性乳腺癌(TNBC)的标准处理方式,在新辅助方案中添加铂类药物能显著提高病理学完全缓解率和远期生存率。然而,目前国内外指南对铂类在TNBC新辅助治疗中的应用推荐仍存在差异。因此,由乳腺外科、乳腺内科、肿瘤科等相关领域专家组成的专家组成员综合参考国内外指南以及重要文献,共同编写本共识,对TNBC新辅助治疗方案、铂类药物作用机制、铂类在TNBC新辅助治疗和辅助治疗中的应用价值、铂类疗效预测因子及治疗相关不良反应等进行循证证据分析,提炼核心观点,并进行了专家组意见投票,以期对铂类在TNBC新辅助治疗中的临床应用提供建议和指导。Neoadjuvant therapy is the standard approach for early-stage high-risk triple negative breast cancer(TNBC)and the addition of platinum-based drugs to neoadjuvant regimens significantly improves pathological complete response rates and long-term survival of patients.However,there are still discrepancies in the recommendations for the application of platinum-based drugs in neoadjuvant therapy for TNBC between domestic and international guidelines.Therefore,a consensus panel of experts from the departments of breast surgery,internal medicine and oncology has compiled this consensus,integrating domestic and international guidelines and important literature.This consensus provides evidence-based analysis,key opinion extraction,and expert opinion voting on topics including neoadjuvant therapy regimens for TNBC,the mechanism of platinum-based drug action,the application value of platinum-based drugs in neoadjuvant therapy and adjuvant therapy for TNBC,predictive factors for platinum efficacy,and treatment-related adverse reactions,aiming to provide recommendations and guidances for the clinical application of platinum-based drugs in neoadjuvant therapy for TNBC.

关 键 词：三阴性乳腺癌 铂类 新辅助治疗 共识 

分 类 号：R737.9[医药卫生—肿瘤]